食管鳞癌新辅助治疗现状与争议

手术是治疗可切除食管鳞癌的首选治疗方案,然而对于局部进展期患者,食管癌的治疗更多强调多学科综合治疗,但目前食管癌的最佳综合治疗策略尚无统一标准。近年来,新辅助治疗在临床上受到学者的广泛关注,但仍存在诸多争议,包括新辅助治疗方案的选择、新辅助治疗后手术时机的选择、新辅助治疗后术后辅助治疗的选择、新辅助与辅助治疗的选择以及新辅助治疗敏感性检测等。本文就目前食管鳞癌新辅助治疗的现状和存在的争议做一综述。

Current status and controversy of neoadjuvant therapy for esophageal squamous cell carcinoma

Surgery is the first choice of treatment for resectable esophageal squamous cell carcinoma. However, for locally advanced patients, the treatment of esophageal cancer requires a more multidisciplinary, comprehensive approach. Nevertheless, there is no unified standard that defines the best comprehensive treatment strategy for esophageal cancer. In recent years, neoadjuvant therapy has been widely considered as the best treatment by practitioners, but there are still many controversies, including those related to the selection of a neoadjuvant therapy scheme, timing of surgery after neoadjuvant therapy, choice of postoperative adjuvant therapy after neoadjuvant therapy, choice of neoadjuvant and adjuvant therapy, and sensitivity testing of neoadjuvant therapy. In this paper, the present situation and controversies regarding the application of neoadjuvant therapy for esophageal squamous cell carcinoma are reviewed systematically.